Hayden E. Klein

Urge-to-cough and cough symptoms were the 2 main domains of a 51-item framework to measure cough severity.

Research shows that disease activity level did not correlate with fat mass percentage among individuals with rheumatoid arthritis (RA).

Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, explains ways artificial intelligence (AI) is being used in dermatology, including smartphone applications, at the 2022 American Academy of Dermatology Annual Meeting.

Bernice Kwong, MD, clinical professor of dermatology, Stanford University, expands on her session about graft-versus-host disease diagnosis and management presented at the 2022 American Academy of Dermatology Annual Meeting, emphasizing the importance of the relationship between patients and doctors.

David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, sat down to discuss comorbidities newly associated with atopic dermatitis at the 2022 American Academy of Dermatology Annual Meeting.

Adults living with HIV receiving integrase strand transfer inhibitor (INSTI)–based antiretroviral therapy (ART) had a 76% higher incidence of hypertension compared with adults receiving non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.

The lack of racial representation in dermatology education prompted the launch of Project IMPACT, explained Art Papier, MD, dermatologist, CEO, VisualDx at the 2022 American Academy of Dermatology Annual Meeting.

Monthly parainfluenza virus incidence rates were nearly 6 times higher in September 2021 vs the second highest reported monthly incidence rates among children 4 years and younger in Finland in the last decade, following lifting of COVID-19–related restrictions.

Patients aged 75 years and older who received a rheumatoid arthritis (RA) diagnosis 2 years ago or less had the highest risk of developing primary open-angle glaucoma (POAG).

Variations between current core outcome sets and how trials are actually measuring self-management among patients with inflammatory arthritis (IA) show the need for further established outcome domains.

Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.

William Schaffner, MD, medical director at the National Foundation for Infectious Diseases (NFID), and Patsy Stinchfield, RN, MS, CPNP, president-elect of NFID, explain how COVID-19 testing developments have opened doors for developments in respiratory syncytial virus (RSV) testing.

Low functional status based on Duke Activity Status Instrument score was associated with higher cardiometabolic risk among individuals 45 years and older living with HIV, this new multinational cohort study found.

Incident end-stage kidney disease cases more than doubled among Asian individuals, and prevalent cases more than tripled for Asian, Native Hawaiian or other Pacific Islander, and Hispanic individuals.

Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, talks about advancements in standards of care for uncommon cancers, including cholangiocarcinoma.

The genetically-predicted risk of rheumatoid arthritis (RA) was positively associated with an increased risk of inflammatory bowel disease (IBD) and potentially with its main subtypes, ulcerative colitis and Crohn disease.

Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss their hopes for their findings and how genetic data are being used in health care.

Using telemedicine to monitor patients with rheumatoid arthritis (RA) initiating disease-modifying antirheumatic drugs (DMARDs) was highly cost-effective and resulted in similar health outcomes compared with in-person monitoring.

Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain their study's implications for providers and how age plays a role in genetic variant penetrance.

The American College of Rheumatology (ACR) has released updated guidelines on pharmacologic and nonpharmacologic treatments for juvenile idiopathic arthritis.

An analysis of 2019 claims data for California Medicaid enrollees shows large disparities in HIV pre-exposure prophylaxis (PrEP) uptake, especially among Black individuals.

Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, explains the delivery mechanism and benefits of Xipere for macular edema.

Natalie Dickson, MD, president and chief strategy officer of Tennessee Oncology, discusses Tennessee Oncology's role in the discussion to reform 340B.

According to the study, rheumatoid arthritis (RA)-associated autoimmunity was not linked to increased cardiovascular (CV) event risk, suggesting systemic inflammation is likely required for precipitating CV events.

Sunil Verma, MD, senior vice president and global head of oncology, medical, at AstraZeneca, discusses safety findings of the TOPAZ-1 trial.

Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.

Although thousands of new substance use disorder treatment facilities that offer medication for opioid use disorder were opened between 2017 and 2020, the proportion of facilities that also offered HIV and hepatitis C virus (HCV) testing hardly changed.

A phase 3 trial showed that nirsevimab was effective in preventing respiratory syncytial virus (RSV)-associated lower respiratory tract infection in healthy late-preterm and term infants.